Physician profile
Harold Schick
NPI 1376550459
$2,310.43
in general payments reported to CMS, 2019-2025
14 companies · $574 in 2025
The $574 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $68.35 · 2021: $92.57 · 2022: $305 · 2023: $585 · 2024: $489 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $765.28 | 2022-2025 | Hydrus Microstent, Voyager Dslt, Argos |
| Abbvie INC. | $322.03 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| Glaukos Corporation | $273.47 | 2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Gs-M-Is-Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Bausch & Lomb Americas INC. | $270.86 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $159.75 | 2019-2021 | |
| Allergan, INC. | $117.58 | 2019-2021 | |
| Amgen INC. | $88.78 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $69.49 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $57.79 | 2024-2025 | Xdemvy |
| Optos, INC. | $49.61 | 2020 | |
| Sight Sciences, INC. | $39.71 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $38.11 | 2024 | Lumera 700 |
| Akorn, INC. | $29.71 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Schick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.